Vorinostat

被引：364

作者：

Grant, Steven ^{[1
]}

Easley, Chris

Kirkpatrick, Peter

机构：

[1] Virginia Commonwealth Univ, Med Coll Virginia, Div Hematol Oncol, Richmond, VA 23298 USA

[2] IMS Hlth, London NW1 6JB, England

来源：

NATURE REVIEWS DRUG DISCOVERY | 2007年 / 6卷 / 01期

关键词：

D O I：

10.1038/nrd2227

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Vorinostat (Zolinza; Merck) was approved by the US FDA in October 2006 for the treatment of cutaneous manifestations in patients with cutaneous T-cell lymphoma who have progressive, persistent or recurrent disease on or following two systemic therapies. It is the first in a new class of anticancer agents that inhibit histone deacetylases, which have a key role in the epigenetic regulation of gene expression.

引用

页码：21 / 22

页数：2

共 12 条

[1] Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90 - A novel basis for antileukemia activity of histone deacetylase inhibitors [J].

Bali, P ;

Pranpat, M ;

Bradner, J ;

Balasis, M ;

Fiskus, W ;

Guo, F ;

Rocha, K ;

Kumaraswamy, S ;

Boyapalle, S ;

Atadja, P ;

Seto, E ;

Bhalla, K .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2005, 280 (29) :26729-26734

[2] Anticancer activities of histone deacetylase inhibitors [J].

Bolden, Jessica E. ;

Peart, Melissa J. ;

Johnstone, Ricky W. .

NATURE REVIEWS DRUG DISCOVERY, 2006, 5 (09) :769-784

[3]

DUVIC M, 2006, BLOOD 0907

[4] Drug Insight: histone deacetylase inhibitors - development of the new targeted anticancer agent suberoylanilide hydroxamic acid [J].

Kelly, WK ;

Marks, PA .

NATURE CLINICAL PRACTICE ONCOLOGY, 2005, 2 (03) :150-157

[5] Immunopathogenesis and therapy of cutaneous T cell lymphoma [J].

Kim, EJ ;

Hess, S ;

Richardson, SK ;

Newton, S ;

Showe, LC ;

Benoit, BM ;

Ubriani, R ;

Vittorio, CC ;

Junkins-Hopkins, JM ;

Wysocka, M ;

Rook, AH .

JOURNAL OF CLINICAL INVESTIGATION, 2005, 115 (04) :798-812

[6] Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation [J].

Richon, VM ;

Sandhoff, TW ;

Rifkind, RA ;

Marks, PA .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (18) :10014-10019

[7] Second generation hybrid polar compounds are potent inducers of transformed cell differentiation [J].

Richon, VM ;

Webb, Y ;

Merger, R ;

Sheppard, T ;

Jursic, B ;

Ngo, L ;

Civoli, F ;

Breslow, R ;

Rifkind, RA ;

Marks, PA .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (12) :5705-5708

[8] A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases [J].

Richon, VM ;

Emiliani, S ;

Verdin, E ;

Webb, Y ;

Breslow, R ;

Rifkind, RA ;

Marks, PA .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (06) :3003-3007

[9] Selective killing of oncogenically transformed cells through a ROS-mediated mechanism by β-phenylethyl isothiocyanate [J].

Trachootham, Dunyaporn ;

Zhou, Yan ;

Zhang, Hui ;

Demizu, Yusuke ;

Chen, Zhao ;

Pelicano, Helene ;

Chiao, Paul J. ;

Achanta, Geetha ;

Arlinghaus, Ralph B. ;

Liu, Jinsong ;

Huang, Peng .

CANCER CELL, 2006, 10 (03) :241-252

[10] Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors [J].

Ungerstedt, JS ;

Sowa, Y ;

Xu, WS ;

Shao, Y ;

Dokmanovic, M ;

Perez, G ;

Ngo, L ;

Holmgren, A ;

Jiang, X ;

Marks, PA .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2005, 102 (03) :673-678

← 1 2 →